← All trials
NCT06103201
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2023
- Primary completion
- Nov 26, 2025
- Completion date
- Nov 26, 2026
- First posted
- Oct 26, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MarylandLead sponsor
- University of MarylandOverall official - principal investigator
- University of MarylandReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.